Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ANVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ANVS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Annovis Bio Inc

ANVS
Current price
2.65 USD -0.12 USD (-4.33%)
Last closed 2.74 USD
ISIN US03615A1088
Sector Healthcare
Industry Biotechnology
Exchange NYSE
Capitalization 51 638 432 USD
Yield for 12 month -76.61 %
1Y
3Y
5Y
10Y
15Y
ANVS
21.11.2021 - 28.11.2021

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14.25 USD

P/E Ratio

Dividend Yield

Financials ANVS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ANVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

EBITDA
Operating Margin TTM
Price to Earnings
Return On Assets TTM -91.05 %
PEG Ratio
Return On Equity TTM -280.78 %
Wall Street Target Price 14.25 USD
Revenue TTM
Book Value 1.23 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.24 USD
Diluted Eps TTM -2.24 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ANVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -3.57
Price Book MRQ 2.17

Technical Indicators ANVS

For 52 Weeks

1.11 USD 11.69 USD
50 Day MA 2.33 USD
Shares Short Prior Month 1 959 704
200 Day MA 4.16 USD
Short Ratio 3.74
Shares Short 2 205 405
Short Percent 13.20 %